Band 55
Progress in Drug Research
Aus der Reihe
Progress in Drug Research
-
- Hardcover
- Taschenbuch ausgewählt
- eBook
-
Sprache:Englisch
-
Auflage:Softcover reprint of the original 1st ed. 2000
- Softcover reprint of the original 1st ed. 2002 195,99 €
- Softcover reprint of the original 1st ed. 2002 195,99 €
- Softcover reprint of the original 1st ed. 2001 97,99 €
- Softcover reprint of the original 1st ed. 2000 49,99 €
- Softcover reprint of the original 1st ed. 2000 49,99 € ausgewählt
- 1. Auflage 95,99 €
- Softcover reprint of the original 1st ed. 2003 195,99 €
- Softcover reprint of the original 1st ed. 1999 49,99 €
- Softcover reprint of the original 1st ed. 1998 49,99 €
- Softcover reprint of the original 1st ed. 1998 97,99 €
- Softcover reprint of the original 1st ed. 1997 49,99 €
- Softcover reprint of the original 1st ed. 1985 49,99 €
- Softcover reprint of the original 1st ed. 1989 49,99 €
49,99 €
inkl. gesetzl. MwSt.,
Lieferung nach Hause
Beschreibung
Produktdetails
Einband
Taschenbuch
Erscheinungsdatum
30.10.2012
Verlag
Springer BaselSeitenzahl
336
Maße (L/B/H)
25,4/17,8/1,9 cm
Gewicht
662 g
Auflage
Softcover reprint of the original 1st ed. 2000
Sprache
Englisch
ISBN
978-3-0348-9544-6
Hepatitis C virus (HCV) was first identified in 1989 as the etiologic agent of non-A, non-B hepatitis [1] and is currently recognized as the leading cause of chronic liver disease worldwide. In contrast to hepatitis B virus infection, in which only about 5% of adult infections become chronic, more than 80% of HCV-infected patients develop chronic hepatitis. Moreover, 20-50% of those persistently infected with HCV will develop liver cirrhosis and hepatocellu lar carcinoma (HCC) [2]. It is estimated that there are 10,000 deaths in the USA per year due to chronic liver failure or HCC [3]. In addition, HCV dis 25-50% of all liver transplants in US centers, and the ease is responsible for recurrence of HCV infection following liver transplantation is universal [4]. Typically, HCV disease emerges after a 10-20 year period during which symp toms, if they exist at all, are mild and non-specific. Although the prevalence varies greatly among different countries, it has been estimated that up to 170 million people (3% of the world's population), are infected with HCV [5]. A recent study in the USA found that 65% of all HCV-infected persons are 30 to 49 years old [6].
Kundinnen und Kunden meinen
Verfassen Sie die erste Bewertung zu diesem Artikel
Helfen Sie anderen Kund*innen durch Ihre Meinung
Kurze Frage zu unserer Seite
Vielen Dank für dein Feedback
Wir nutzen dein Feedback, um unsere Produktseiten zu verbessern. Bitte habe Verständnis, dass wir dir keine Rückmeldung geben können. Falls du Kontakt mit uns aufnehmen möchtest, kannst du dich aber gerne an unseren Kund*innenservice wenden.
zum Kundenservice